SAUDI ARABIA —Middle East Pharmaceutical Industries Co. has secured a SAR 60 million working capital financing facility from the Saudi Industrial Development Fund (SIDF), under an agreement signed on 8 November 2026. The funding will be available for a period of two years from the date of receipt and is intended to support the pharmaceutical manufacturer's day-to-day operating requirements, including the financing of its working capital cycle.
The financing arrangement uses existing security over the company's fixed assets and land at the Avalon-2 facility and Central Warehouse. These properties had previously been pledged to SIDF in connection with an existing medium-term loan and will also serve as collateral for the new facility. In addition, the company has provided a promissory note covering the full financing amount of SAR 60 million. No related parties are involved in the transaction.
Access to working capital is particularly important for pharmaceutical manufacturers, whose operations require continuous procurement of active pharmaceutical ingredients, packaging materials and other production inputs. Funding availability also supports inventory management, manufacturing continuity and the management of payment cycles involving distributors, healthcare providers and other customers. The new facility therefore provides Middle East Pharmaceutical Industries with additional financial resources to manage routine operational commitments over the financing period.
Middle East Pharmaceutical Industries operates in Saudi Arabia's pharmaceutical manufacturing sector, producing medicines for the domestic healthcare market. The Saudi Industrial Development Fund (SIDF) is a government-backed development financing institution that provides financial support to industrial activities and contributes to the expansion of the Kingdom's manufacturing base.
The agreement also illustrates the role of specialised development financing in supporting the operational requirements of Saudi Arabia's pharmaceutical industry. Domestic manufacturers require dependable access to financing to maintain production capacity, manage supply-chain requirements and respond to demand from the healthcare sector. Working capital facilities can help address short-term liquidity requirements without relying exclusively on internally generated cash flows.
For Middle East Pharmaceutical Industries, the two-year facility offers additional liquidity while extending the use of assets already pledged under its existing borrowing arrangements. However, the reuse of collateral means that the company's secured asset base remains linked to multiple financing obligations with the same lender. For investors and other stakeholders, the arrangement highlights the importance of monitoring working capital efficiency, borrowing commitments and the company's ability to generate sufficient operating cash flow to meet its financial obligations.